Literature DB >> 27161773

Course and Outcome of Early European Lyme Neuroborreliosis (Bannwarth Syndrome): Clinical and Laboratory Findings.

Katarina Ogrinc1, Lara Lusa2, Stanka Lotrič-Furlan1, Petra Bogovič1, Daša Stupica1, Tjaša Cerar3, Eva Ružić-Sabljić3, Franc Strle1.   

Abstract

BACKGROUND: Information on the course and outcome of early European Lyme neuroborreliosis is limited.
METHODS: The study comprised 77 patients (38 males, 39 females; median age, 58 years) diagnosed with painful meningoradiculitis (Bannwarth syndrome) who were followed up for 1 year at a single center.
RESULTS: Duration of neurological symptoms before diagnosis was 30 (interquartile range, 14-50) days. The most frequent symptoms/signs were radicular pain (100%), sleep disturbances (75.3%), erythema migrans (59.7%), headache (46.8%), fatigue (44.2%), malaise (39%), paresthesias (32.5%), peripheral facial palsy (PFP) (36.4%), meningeal signs (19.5%), and pareses (7.8%). Cerebrospinal fluid (CSF) analysis revealed lymphocytic/monocytic pleocytosis, elevated protein concentration, and intrathecal synthesis of borrelial immunoglobulin M and immunoglobulin G antibody in 100%, 81.1%, 63%, and 88.7% of patients, respectively. Borreliae (predominantly Borrelia garinii) were isolated from CSF, skin, and blood in 15.6%, 40.6%, and 2.7% of patients, respectively. The outcome after 14-day treatment with ceftriaxone was favorable in 87.8% of patients. Control CSF examination at 3 months showed decreased leukocyte counts in all patients; however, 23.3% still had pleocytosis (>10 × 10(6) cells/L). A model based on pretreatment data and the findings at the end of 14-day antibiotic treatment accurately predicted which patients would have an unfavorable outcome 6 or 12 months after treatment.
CONCLUSIONS: Our patients had fewer pretreatment neurological complications (PFP, pareses) than reported for Bannwarth syndrome decades ago, probably as the result of earlier recognition and prompt antibiotic treatment. Unfavorable outcome was rare and was predicted by the continued presence of symptoms 14 days after commencement of treatment.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Bannwarth syndrome; Borrelia burgdorferi sensu lato; Borrelia garinii; Lyme neuroborreliosis; outcome

Mesh:

Substances:

Year:  2016        PMID: 27161773     DOI: 10.1093/cid/ciw299

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Lyme Neuroborreliosis.

Authors:  Sebastian Rauer; Stefan Kastenbauer; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Rick Dersch
Journal:  Dtsch Arztebl Int       Date:  2018-11-09       Impact factor: 5.594

Review 2.  Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Authors:  Juan Carlos Garcia-Monco; Jorge L Benach
Journal:  Ann Neurol       Date:  2019-01       Impact factor: 10.422

Review 3.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

4.  Cranial neuropathy and severe pain due to early disseminated Borrelia burgdorferi infection.

Authors:  Derek Ebner; Kelsey Smith; Daniel DeSimone; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2018-01-23

Review 5.  Challenges in the Diagnosis and Treatment of Lyme Disease.

Authors:  Robert T Schoen
Journal:  Curr Rheumatol Rep       Date:  2020-01-07       Impact factor: 4.592

6.  Neuroborreliosis.

Authors:  John J Halperin
Journal:  J Neurol       Date:  2016-11-24       Impact factor: 4.849

Review 7.  A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease.

Authors:  Gary P Wormser; Franc Strle; Eugene D Shapiro; Raymond J Dattwyler; Paul G Auwaerter
Journal:  Diagn Microbiol Infect Dis       Date:  2016-11-12       Impact factor: 2.803

Review 8.  Clinical spectrum of Lyme disease.

Authors:  Jesus Alberto Cardenas-de la Garza; Estephania De la Cruz-Valadez; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-19       Impact factor: 3.267

Review 9.  Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States.

Authors:  Elitza S Theel; Maria E Aguero-Rosenfeld; Bobbi Pritt; Patricia V Adem; Gary P Wormser
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

10.  Lyme Disease in Humans.

Authors:  Justin D Radolf; Klemen Strle; Jacob E Lemieux; Franc Strle
Journal:  Curr Issues Mol Biol       Date:  2020-12-11       Impact factor: 2.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.